摘要
目的探究替吉奥、奥沙利铂联合用于进展期胃癌患者治疗中的临床效果。方法方便选取2017年11月-2019年10月至该院就诊的63例进展期胃癌患者作为该次研究的研究对象。以掷硬币分组法将患者分为参照组(共31例,给予卡培他滨、奥沙利铂联合治疗)和治疗组(共32例,给予替吉奥、奥沙利铂联合治疗)。对比两组患者的近期疗效、不良反应和生存质量。结果两组治疗有效率对比,差异无统计学意义(χ^2=0.390,P=0.532)。治疗组疾病控制率明显高于参照组(χ^2=4.259,P=0.039)。治疗组患者的恶心呕吐、腹泻、乏力、嗜中性粒细胞减少以及周围神经毒性等不良发应的发生率与参照组相比,差异无统计学意义(χ^2=0.253、0.075、0.198、0.494、0.152,P=0.615,0.784,0.656,0.482,0.697)。治疗组KPS评分改善率为93.75%高于参照组的74.19%(χ^2=4.509,P=0.034)。结论替吉奥、奥沙利铂联合用于进展期胃癌患者治疗中的临床效果与卡培他滨、奥沙利铂联合治疗(FOLFOX4方案)的疗效相当,在保证近期疗效的同时,不良反应耐受性好,同时对患者的生存质量有积极影响,可推广使用。
Objective To explore the clinical effect of the combination of tegio and oxaliplatin in the treatment of patients with advanced gastric cancer.Methods Sixty-three patients with advanced gastric cancer who visited the hospital from November 2017 to October 2019 were convenient selected as the subjects of this study.The patients were divided into a reference group(a total of 31 cases,given capecitabine and oxaliplatin combination therapy)and a treatment group(a total of 32 cases,given tiagio and oxaliplatin combination therapy)by coin tossing.Compare the short-term efficacy,adverse reactions and quality of life of the two groups of patients.Results There was no significant difference in treatment efficiency between the two groups(χ^2=0.390,P=0.532).The disease control rate of the treatment group was significantly higher than that of the reference group(χ^2=4.259,P=0.039).Compared with the reference group,the incidence of adverse reactions such as nausea,vomiting,diarrhea,fatigue,neutropenia,and peripheral neurotoxicity in the treatment group was not statistically significant(χ^2=0.253,0.075,0.198,0.494,0.152,P=0.615,0.784,0.656,0.482,0.697).The improvement rate of KPS score in the treatment group was 93.75%,which was higher than 74.19%in the reference group(χ^2=4.509,P=0.034).Conclusion The clinical effect of the combination of tegio and oxaliplatin in the treatment of patients with advanced gastric cancer is comparable to that of capecitabine and oxaliplatin(FOLFOX4 regimen).Adverse effects are well tolerated while ensuring near-term efficacy,while having a positive impact on patient quality of life and can be promoted for use.
作者
季名扬
宫美丽
JI Ming-yang;GONG Mei-li(Department of Oncology,General Staff Hospital of Liaoyuan Mining(Group)Co.,Ltd,Liaoyuan,Jilin Province,136201 China)
出处
《中外医疗》
2020年第23期84-86,共3页
China & Foreign Medical Treatment
关键词
替吉奥
奥沙利铂
卡培他滨
进展期胃癌
近期疗效
不良反应
生存质量
Tegio
Oxaliplatin
Capecitabine
Advanced gastric cancer
Short-term efficacy
Adverse reactions
Quality of life
